innoModel-Provide preclinical pharmacological services

Tumor Immunity Dual Source Platform

Combining PDX and the humanized immune system platform, a tumor immunotherapy efficacy platform that is closer to clinical practice.

Tumor Immunity Platform

Provide various tumor immunotherapy efficacy models, including syngeneic models, genetically engineered syngeneic models, and humanized immune system models.

In Vivo Pharmacodynamics Platform

Provide tumor and tumor immunotherapy new drug developers with efficacy testing, including next-generation PDX models and Ba/F3 engineered cell line in vivo experiments.

In vitro pharmacodynamics platform

Provide a variety of in vitro experimental services, including tumor cell killing experiments, ADCC, CDC, and other tumor immune cell killing experiments.

Tumor Immunity Dual Source Platform

Combining PDX and the humanized immune system platform, a tumor immunotherapy efficacy platform that is closer to clinical practice.

R & D service platform

R&D SERVICE PLATFORM

Humanized mice for l/O

iHuPBMC-T ， iHuPBMC-NK，iHuPBMC-B， iHuPBMC-Donor screening and QC, iHuPBMC-OncVax medicine research institutions and cancer patients with innovative experimental animal models and in vitro research models.

Oncology in vivo

CDX models，iHuPDX models， Orthotopic models， Orthotopic mouse brain models

in vitro cytotoxicity test

Patient-derived tumor cell screening, 3D orgnoid, IC50, Immunue cells mediated tumor killing assays immunotherapy to provide close to the clinical trials of a new generation of animal models.

Syngeneic models for l/O

Syngeneic models, NK function assay in SCID mice, Genetically engineered mouse models

Cancer vaccine evaluation

Syngeneic-OncVax for cancer vaccine, MHC humanized mouse

Cell therapy

Car-T,Car-NK, Car-T in MHC/KO mice, Host vs graft (HVG)

in vitro immune assay

ELISpot, ELISA, FACS, qPCR

Non-GLP tox

GVHD experimental platform， Immunogenicity Testing

PDX model

Lymphoma (LY),Chronic myeloproliferitve neoplasm (CMP), Myelodisplasic syndrome (MDS)

CDX model

Eosinophilia (EOS), Leukemia (LK), Myeloma (MYMA), Mastocytosis (MAS), Musculoskeletal and vascular systems

Tumor and tumor immune new drug research and development tool library

Syngeneic model

Nervous system (NS),Urinary system (US),Endocrine System (ES), Female reproductory system (FRS)

Database

Car-T,Car-NK, Car-T in MHC/KO mice, Host vs graft (HVG)

InnoModels News

InnoModels has a stable immune system humanized mouse model platform (HIS) and a human tumor allotransplantation platform (PDX) in China.

News dynamics

InnoModels always adhere to the quality of development, quality of survival principle, to promote the company to the development of collectivized economy

Industry dynamics

Creative biology: exploring the innovative way of humanized model of immune system

News dynamics

InnoModels Biotechnology: Exploring the Innovative Path of Humanized Models of the Immune System

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients

News dynamics

Overview of iHuPBMC-T Technology from InnoModels Biotechnology

In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.

News dynamics

Introducing the Patent of PBMC Immune System Reconstruction Capability Detection Method and Application by InnoModels Biotechnology

Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models

News dynamics

InnoModels Biotechnology ELISpot platform: a powerful tool to precisely analyze the immune response

With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality

About InnoModels

InnoModels Biotechnology (Beijing) Co., Ltd. aims to serve new drug research and development enterprises, translational medicine research institutions and cancer patients with innovative experimental animal models and in vitro research models. Gen die creature has domestic stability of the humanized mice immune system model (ihs) platform, and anthropogenic tumor allografts platform (symbol), focusing on tumor and tumor immune pharmacodynamics CRO services, translational medicine research service, individualized medicine, service transformation of new drug research and development enterprise, medical researchers, cancer patients, is dedicated to the research and development of tumor and tumor immunotherapy to provide close to the clinical trials of a new generation of animal models.

Chuangmo Biotechnology (Beijing) Co., Ltd.

Telephone:+8615010000264 +8613810723384
E-mail:cndw@imodels.tech
Address: Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Chuangmo Biotechnology (Beijing) Co., Ltd

SEO

Business License